Phospho-RB1 (S780) Recombinant Monoclonal Antibody

說明書

中文名稱：

磷酸化-RB1 (S780)重組抗體
貨號：

CSB-RA019386A780phHU
規格：

￥1320
圖片：
IHC image of CSB-RA019386A780phHU diluted at 1:100 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

Immunofluorescence staining of K562 cells with CSB-RA019386A780phHU at 1:100,counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4℃. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG (H+L).

Immunoprecipitating Phospho-RB1 in Hela whole cell lysate
Lane 1: Rabbit control IgG(1μg)instead of CSB-RA019386A780phHU in Hela whole cell lysate. For western blotting,a HRP-conjugated Protein G antibody was used as the secondary antibody (1/2000)
Lane 2: CSB-RA019386A780phHU(3μg)+ Hela whole cell lysate(1mg)
Lane 3: Hela whole cell lysate (20μg)
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品描述：

Phospho-RB1 (S780) Recombinant Monoclonal Antibody（CSB-RA019386A780phHU）是針對RB1蛋白S780磷酸化位點開發的高特異性重組抗體。RB1（Retinoblastoma Protein）是細胞周期調控的核心因子，其磷酸化狀態直接參與細胞周期G1/S期轉換的調控。S780位點的磷酸化是RB1功能失活的關鍵標志之一，與細胞增殖、分化及腫瘤發生密切相關。本抗體通過重組表達技術制備，經ELISA、免疫組化（IHC）、免疫熒光（IF）和免疫沉淀（IP）等多平臺嚴格驗證，在IHC實驗中推薦使用1:50-1:200稀釋比例，IF實驗適用1:20-1:200稀釋范圍，IP實驗則適配1:200-1:1000的寬泛稀釋梯度，展現出色的抗原結合能力和低背景干擾特性。該產品適用于檢測多種樣本中RB1 S780位點的磷酸化動態，為研究細胞周期調控機制、腫瘤發生發展中的信號通路異常以及DNA損傷應答等基礎科研領域提供精準檢測工具。其重組單克隆特性確保批次間高度一致性，滿足蛋白互作研究、亞細胞定位分析及磷酸化修飾相關實驗的嚴格要求，是探索RB1功能調控及疾病相關分子機制的高效試劑。
Uniprot No.：

P06400
基因名：

RB1
別名：

Exon 17 tumor GOS561 substitution mutation causes premature stop antibody; GOS563 exon 17 substitution mutation causes premature stop antibody; OSRC antibody; Osteosarcoma antibody; p105-Rb antibody; P105RB antibody; PP105 antibody; pp110 antibody; PPP1R130 antibody; pRb antibody; Prepro retinoblastoma associated protein antibody; Protein phosphatase 1 regulatory subunit 130 antibody; Rb antibody; RB transcriptional corepressor 1 antibody; RB_HUMAN antibody; RB1 antibody; RB1 gene antibody; Retinoblastoma 1 antibody; Retinoblastoma suspectibility protein antibody; Retinoblastoma-associated protein antibody
反應種屬：

Human
免疫原：

A synthesized peptide derived from Human Phospho-RB1 (S780)
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號：

2E9
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
產品提供形式：

Liquid
應用范圍：

ELISA, IHC, IF, IP

推薦稀釋比：

Application	Recommended Dilution
IHC	1:50-1:200
IF	1:20-1:200
IP	1:200-1:1000

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
Immunoprecipitation (IP) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Tumor suppressor that is a key regulator of the G1/S transition of the cell cycle. The hypophosphorylated form binds transcription regulators of the E2F family, preventing transcription of E2F-responsive genes. Both physically blocks E2Fs transactivating domain and recruits chromatin-modifying enzymes that actively repress transcription. Cyclin and CDK-dependent phosphorylation of RB1 induces its dissociation from E2Fs, thereby activating transcription of E2F responsive genes and triggering entry into S phase. RB1 also promotes the G0-G1 transition upon phosphorylation and activation by CDK3/cyclin-C. Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases SUV39H1, KMT5B and KMT5C, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Inhibits the intrinsic kinase activity of TAF1. Mediates transcriptional repression by SMARCA4/BRG1 by recruiting a histone deacetylase (HDAC) complex to the c-FOS promoter. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex.; (Microbial infection) In case of viral infections, interactions with SV40 large T antigen, HPV E7 protein or adenovirus E1A protein induce the disassembly of RB1-E2F1 complex thereby disrupting RB1's activity.
基因功能參考文獻：
1. Concurrent mutations, in genes such as CDKN2B or RB1, were associated with worse clinical outcome in lung adenocarcinoma patients with EGFR active mutations. PMID: 29343775
2. Mutational screening of germline RB1 gene in Vietnamese patients with retinoblastoma reveals three novel mutations. PMID: 29568217
3. Analyses with phospho-defective and phospho-mimetic mutants of FoxM1b identified a critical role of the Plk1 phosphorylation sites in regulating the binding of FoxM1b to Rb and DNMT3b. PMID: 28387346
4. The accumulation of sequence variations in RB1 gene might influence Greek patients' susceptibility towards the progression of cervical neoplasia. PMID: 30303478
5. vitiligo lesions exhibited dysregulated SUMOylation and deSUMOylation in keratinocytes, dysregulation of the cell cycle progression was observed in SUMO1 knockdown HaCaT cells and the deSUMOylation of Rb in keratinocytes may serve an important role in the development of vitiligo. PMID: 30066925
6. The Rb1 tumor suppressor gene modifies telomeric chromatin architecture by regulating TERRA expression. PMID: 28169375
7. These findings demonstrate that developmental stage-specific as well as species- and cell type-specific features sensitize to RB1 inactivation and reveal the human cone precursors' capacity to model retinoblastoma initiation, proliferation, premalignant arrest, and tumor growth. PMID: 30213853
8. Low pRB expression is associated with mouth Cancer. PMID: 30275188
9. Control of the Restriction Point by Rb and p21. PMID: 30111539
10. results showed that a) alterations of the p53 and Rb pathways are associated with high proliferation of tumor cells in BUC and b) high expression of cell-cycle proteins is associated with adverse histopathological parameters of these tumors PMID: 29970521
11. he present result indicated that vascular smooth proliferation is regulated by activation of the NF-kappaB p65/miR17/RB pathway. As NF-kappaB p65 signalling is activated in and is a master regulator of the inflammatory response, the present findings may provide a mechanism for the excessive proliferation of VSMCs under inflammation during vascular disorders and may identify novel targets for the treatment of vascular d... PMID: 29115381
12. Reduced RB expression in medullary thyroid cancer is associated with decreased patient survival in univariate and multivariable analyses, independent from patient age at surgery or advanced TNM stage. PMID: 29105562
13. According to immunohistochemistry and immunoblot analysis, the expression levels of cyclin D1, cyclin E, pRb, and Ki67 in psoriasis lesions decreased after treatment and were similar with those in the normal group PMID: 29115643
14. Data indicate that nuclear envelope rupture in cancer cells is likely due to loss of either the Rb or the p53 pathway. PMID: 28811362
15. Altered pRb is frequently expressed in gastric carcinoma, inversely correlates with tumor invasion and tumor stage suggesting an early event in gastric carcinogenesis. PMID: 28965621
16. results define a network of E2F target genes as susceptible to the regulatory influence of H1.2, where H1.2 augments global association of pRb with chromatin, enhances transcriptional repression by pRb, and facilitates pRb-dependent cell-cycle arrest PMID: 28614707
17. The increased expression of miR-503-5p significantly reduced the expressions of E2F transcription factor 3 (E2F3) mRNA and retinoblastoma protein (Rb)/E2F signaling pathway mRNA in bladder cancer cells. PMID: 29169421
18. Loss of Rb immunolabeling and KRAS mutation are promising molecular markers of the therapeutic response to platinum-based chemotherapy for pancreatic neuroendocrine neoplasm grade-3 (PanNEN-G3), and Rb for neuroendocrine tumor with G3 (NET-G3). PMID: 28455360
19. We recommend intensive ocular screening for patients with germline RB1 mutations for retinoblastoma as well as neuroimaging for pineoblastoma surveillance. There is an approximately 20% risk of developing second primary cancers among individuals with hereditary RB, higher among those who received radiotherapy for their primary RB tumors PMID: 28674118
20. The SNPs rs 216311, rs 1800383 and rs 1800386 associated significantly with bleeding in study subjects. rs1800386 occurred in all with bleeding history, no ethnic variations were noted. PMID: 28091443
21. miR-215 promoted cell migration and invasion of gastric cancer by directly targeting RB1. PMID: 28689850
22. MiR-661 promotes metastasis of non small cell lung cancer through RB/E2F1 signaling and epithelial-mesenchymal transition events. PMID: 28716024
23. RB1 was identified as a direct and functional target of miR-215. RB1 is generally down-regulated in glioma tissues and its expression inversely correlated with miR-215, which is up-regulated in high-grade glioma tissues, and its expression was negatively correlated with miR-215. PMID: 28573541
24. Loss of retinoblastoma in pleomorphic fibroma: An immunohistochemical and genomic analysis. PMID: 28543636
25. Results show that RB1 expression is regulated by cdc37 which facilitates its phosphorylation through increasing CDK4 stability. PMID: 29288563
26. SOX2 overexpression and the loss of Rb1 protein expression might have a pivotal role in the divergent differentiation of pluripotent embryonic-like epithelial cells and the development of esophageal small-cell carcinoma. PMID: 28106103
27. several RB1 alterations associated to retinoblastoma in the human were present in several non-human primates without an apparent pathological effect. PMID: 28401291
28. Results suggest that RB1 is the dominant tumor suppressor PP in MCC, and that inactivation of RB1 by MCPyV-LT is largely sufficient for its growth supporting function in established MCPyV-positive MCC cells. PMID: 27121059
29. the frequency and association of polymorphisms in the TP53 and RB1 genes with clinical characteristics in a group of children with retinoblastoma (RB) in northern Mexico, was examined. PMID: 28210099
30. RB underexpression is associated with tumor cell invasiveness and neuroendocrine differentiation in prostate cancer. PMID: 27015368
31. Authors show that MYC inhibition by Omomyc, a dominant-negative MYC, suppresses the growth of SCLC cells with TP53 and RB1 inactivation carrying MYC, MYCL, or MYCN amplification. PMID: 27105536
32. Data suggest that the platelet derived growth factor receptor alpha (PDGFRalpha)/Stat3 transcription factor/Rb1 protein regulatory axis might represent a potential therapeutic target for glioblastoma (GBM) treatment. PMID: 27344175
33. miR-590 inhibits RB1 and promotes proliferation and invasion of T-cell acute lymphoblastic leukaemia cells PMID: 27036041
34. causative RB1 mutations in most bilateral retinoblastoma (RB) patients and in some unilateral RB patients, including five novel mutations, were identified. PMID: 29261756
35. homozygous loss of RB1 is an independent prognostic marker in multiple myeloma PMID: 28234347
36. In certain contexts, Rb loss enables TRbeta1-dependent suppression of SKP2 as a safeguard against RB1-deficient tumorigenesis. TRbeta2 counteracts TRbeta1, thus disrupting this safeguard and promoting development of RB1-deficient malignancies. PMID: 28972075
37. Expression levels of miR-675-5p in glioma tissues and cells were negatively correlated with RB1 expression at both mRNA and protein levels and promoted cell proliferation and migration. PMID: 28970140
38. Disruption of DREAM and RB-E2F complexes by oncoproteins from DNA tumor viruses leads to upregulation of cell cycle genes and impairs growth-inhibiting pathways, including the p53-mediated downregulation of cell cycle genes. [review] PMID: 28799433
39. A relatively stable genome in retinoblastoma tumor cells is maintained by TRb1 and TRb2-mediated PTTG1 inhibition, counteracting Rb-deficiency-related genomic instability. PMID: 28242412
40. APC/C and pRB interact with each other via the co-activator of APC/C, FZR1, providing an alternative pathway of regulation of G1 to S transition by pRB using a post-translational mechanism. Both pRB and FZR1 have complex roles and are implicated not only in regulation of cell proliferation but also in differentiation, quiescence, apoptosis, maintenance of chromosomal integrity and metabolism. PMID: 27402801
41. Analysis of the spectrum of RB1 variants observed in 60,706 exomes identifies 197 variants that have enough potential to disrupt splicing to warrant further consideration. PMID: 28780672
42. AR also indirectly increases the expression of DNA replication genes through stimulatory effects on other metabolic genes with subsequent CDK activation and Rb hyperphosphorylation. PMID: 27760327
43. Rb gene promoter methylation was more frequent in gastric cancer patients than in controls. PMID: 28319413
44. We report the significance of genetic testing in the early detection and management of retinoblastoma from India. PMID: 26914665
45. Results show that the functional state of protein Rb is inferred to be inactive due its phosphorylation status in the MYCN-amplified retinoblastoma without coding sequence mutations. This makes inactivation of RB1 by gene mutation or by protein phosphorylation, a necessary condition for initiating retinoblastoma tumorigenesis, independent of MYCN amplification. PMID: 28211617
46. Low RB expression is associated with osteosarcoma. PMID: 28655788
47. Loss of RB1 is associated with papillomavirus involvement in Barrett's dysplasia and esophageal adenocarcinoma. PMID: 28722212
48. The epigenetic interaction between Linc00441 and bidirectional transcripted neighbor RB1 may be a de novo theory cutting-point for the inactivation of RB1 in HCC. PMID: 28300839
49. The data indicate that MAZ is essential to bypass MYB promoter repression by RB family members and to induce MYB expression. PMID: 28973440
50. RB inactivation enhances pro-inflammatory signaling through stimulation of the interleukin-6/STAT3 pathway, which directly promotes various malignant features of cancer cells. [review] PMID: 28865172
顯示更多

收起更多
相關疾病：

Childhood cancer retinoblastoma (RB); Bladder cancer (BLC); Osteogenic sarcoma (OSRC)
亞細胞定位：

Nucleus.
蛋白家族：

Retinoblastoma protein (RB) family
組織特異性：

Expressed in the retina. Expressed in foreskin keratinocytes (at protein level).
數據庫鏈接：

HGNC: 9884

OMIM: 109800

KEGG: hsa:5925

STRING: 9606.ENSP00000267163

UniGene: Hs.408528

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human